These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 15780207

  • 1. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
    Ozdemir F, Rodoplu M.
    Chin Med J (Engl); 2005 Mar 05; 118(5):383-90. PubMed ID: 15780207
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M.
    N Engl J Med; 1995 Nov 30; 333(22):1437-43. PubMed ID: 7477143
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME.
    Int J Clin Pract; 2008 Apr 30; 62(4):575-84. PubMed ID: 18324951
    [Abstract] [Full Text] [Related]

  • 12. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N, Ioannou YS, Kyriakou A, Savva SC, Efstathiou E, Savvides I, Christou S.
    Pediatr Endocrinol Rev; 2008 Oct 30; 6 Suppl 1():144-8. PubMed ID: 19337169
    [Abstract] [Full Text] [Related]

  • 13. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, Verbruggen N, Melton ME.
    J Intern Med; 2004 Apr 30; 255(4):503-11. PubMed ID: 15049885
    [Abstract] [Full Text] [Related]

  • 14. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D.
    Arthritis Rheum; 1999 Jun 30; 42(6):1246-54. PubMed ID: 10366118
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M, Balducci S, Schiappoli A, Caliumi C, Petramala L, Cerci S, Cotesta D, D'Erasmo E, Letizia C.
    Ann Ital Med Int; 2003 Jun 30; 18(2):89-98. PubMed ID: 12886826
    [Abstract] [Full Text] [Related]

  • 19. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
    Guven Z, Karadag-Saygi E, Unlu-Ozkan F, Akyuz G.
    Aging Male; 2007 Dec 30; 10(4):197-201. PubMed ID: 18033629
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.